Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial

Published:2017-04 Issue:4 Volume:18 Page:435-445
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Dummer Reinhard,Schadendorf Dirk,Ascierto Paolo A,Arance Ana,Dutriaux Caroline,Di Giacomo Anna Maria,Rutkowski Piotr,Del Vecchio Michele,Gutzmer Ralf,Mandala Mario,Thomas Luc,Demidov Lev,Garbe Claus,Hogg David,Liszkay Gabriella,Queirolo Paola,Wasserman Ernesto,Ford James,Weill Marine,Sirulnik L Andres,Jehl Valentine,Bozón Viviana,Long Georgina V,Flaherty Keith

Publisher

Elsevier BV

Subject

Oncology

Reference34 articles.

1. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271;Boiko;Nature,2010

2. The genetic evolution of melanoma from precursor lesions;Shain;N Engl J Med,2015

3. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas;Krauthammer;Nat Genet,2015

4. NRAS mutation status is an independent prognostic factor in metastatic melanoma;Jakob;Cancer,2012

5. Genomic classification of cutaneous melanoma;Cell,2015

Cited by 402 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. MEK inhibitors in oncology: a patent review and update (2016 - present);Expert Opinion on Therapeutic Patents;2024-09-14

3. Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma;npj Precision Oncology;2024-09-05

4. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

5. Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma;Cancer Treatment Reviews;2024-09